<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21526">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01679912</url>
  </required_header>
  <id_info>
    <org_study_id>P110109</org_study_id>
    <secondary_id>2012-A00044-39</secondary_id>
    <nct_id>NCT01679912</nct_id>
  </id_info>
  <brief_title>A Call Center During HAE Attacks (SOS HAE)</brief_title>
  <acronym>SOS AOH</acronym>
  <official_title>Hereditary Angioedema : Interest From the Use of a Call Center During the Attacks.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial aims to compare morbidity and cost associated with acute attacks of
      hereditary angioedema in patients with an intervention based on a support after a phone call
      to the call center (SOS HAE) from a group of patients does not change their practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators propose a study to determine whether a call center for an acute attack of HAE
      associated with intervention recommendations based on systematic early treatment
      (self-administration at home or by a caregiver) would reduce the morbidity and the
      socioeconomic impact.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of patients hospitalized per year for an observation period of two years at 2 years</measure>
    <time_frame>at 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of patients hospitalized per year for an observation period of two years [Time Frame : 2 years]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalizations per year in intensive care unit [Time Frame : 2 years]</measure>
    <time_frame>at 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of hospitalizations per year in intensive care unit [Time Frame : 2 years]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of emergency departments visits per year [Time Frame : 2 years]</measure>
    <time_frame>at 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalizations [Time Frame : 2 years]</measure>
    <time_frame>at 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of intubations per year [Time Frame : 2 years]</measure>
    <time_frame>at 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of interventions of Emergency Medical System [Time Frame : 2 years]</measure>
    <time_frame>at 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of stop disease and duration [Time Frame : 2 years]</measure>
    <time_frame>at 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality [Time Frame : 2 years]</measure>
    <time_frame>at 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of the hospitalization</measure>
    <time_frame>at 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>total cost : cost of one hospitalization x number of hospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hereditary Angioedema</condition>
  <arm_group>
    <arm_group_label>1: phone to call center</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recommendations to phone to the call center for all the patients who have an acute attack</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: usual strategy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>usual strategy. No intervention (patients does not change their practice)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>phone to the call center</intervention_name>
    <description>recommendations to phone to the call center for all the patients who have an acute attack</description>
    <arm_group_label>1: phone to call center</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with an hereditary angioedema followed in a reference center for bradykinin
             angioedema (CRéAk)

          -  Patient's age ≥ 18 years

          -  Consent to the participation in the study

          -  Affiliated to social security

        Exclusion Criteria:

          -  pregnant woman

          -  recent history of myocardial infarction

          -  recent history of stroke

          -  allergy to icatibant or C1 inhibitor concentrate
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédéric ADNET, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frédéric ADNET, MD,PhD</last_name>
    <phone>33 (0)1 48 96 44 08</phone>
    <email>frederic.adnet@avc.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>SAMU 93 - Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <state>Ile de France</state>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frédéric ADNET, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>August 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hereditary angioedema</keyword>
  <keyword>Emergency Medical Service</keyword>
  <keyword>Health care coast</keyword>
  <keyword>Telephone</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
